Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum.

Détails

ID Serval
serval:BIB_C0A10DE4923A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum.
Périodique
Vaccine
Auteur(s)
Genton B., D'Acremont V., Lurati-Ruiz F., Verhage D., Audran R., Hermsen C., Wolters L., Reymond C., Spertini F., Sauerwein R.
ISSN
1873-2518[electronic], 0264-410X[linking]
Statut éditorial
Publié
Date de publication
2010
Volume
28
Numéro
40
Pages
6573-6580
Langue
anglais
Résumé
The aim of this Phase I/IIa double-blind controlled trial was to test the efficacy of the sporozoite-based malaria vaccine PfCS 282-383 (PfCS102) to protect against Plasmodium falciparum parasitaemia. 16 volunteers were randomized to receive twice 30 μg of PfCS102 formulated in Montanide ISA 720 or ISA 720 alone (control). Two weeks after 2nd immunization, volunteers were challenged using 5 infected mosquitoes. All vaccinees developed antibodies against PfCS102 versus none control. 8/8 vaccinees and 6/6 controls challenged developed malaria parasitaemia. The duration from infection to onset of patent parasitaemia was similar in both groups (214 h in vaccinees and 216 in controls). PfCS102 is safe and immunogenic but provides no protection against artificial challenge in its current formulation.
Mots-clé
Phase IIa, Malaria vaccine, Sporozoite, Plasmodium falciparum, polymerase-chain-reaction, circumsporozoite protein, synthetic polypeptides, infected mosquitos, immune-response, burkina-faso, endemic area, t-cells, safety, peptides
Pubmed
Web of science
Création de la notice
20/10/2010 15:03
Dernière modification de la notice
20/08/2019 15:35
Données d'usage